KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Long-Term Investments for 6 consecutive years, with $93.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments rose 10.96% year-over-year to $93.3 million, compared with a TTM value of $93.3 million through Sep 2025, up 10.96%, and an annual FY2024 reading of $82.3 million, up 24.81% over the prior year.
  • Long-Term Investments was $93.3 million for Q3 2025 at AbCellera Biologics, up from $90.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $93.3 million in Q3 2025 and bottomed at $32.2 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $66.4 million, with a median of $65.9 million recorded in 2023.
  • The sharpest move saw Long-Term Investments surged 161.41% in 2021, then fell 10.68% in 2023.
  • Year by year, Long-Term Investments stood at $50.3 million in 2021, then skyrocketed by 44.14% to $72.5 million in 2022, then fell by 9.08% to $65.9 million in 2023, then rose by 24.81% to $82.3 million in 2024, then rose by 13.37% to $93.3 million in 2025.
  • Business Quant data shows Long-Term Investments for ABCL at $93.3 million in Q3 2025, $90.4 million in Q2 2025, and $81.6 million in Q1 2025.